GUGGENHEIM 3RD ANNUAL HEALTHCARE INNOVATION CONFERENCE - TANGO THERAPEUTICS INC

Explicit Guidance:

• No specific financial guidance (revenue, earnings, margins, capex) provided; company remains in "pre-submission, pre-commercial mode" with no revenue generation currently.
• Phase 3 Frontline Pancreatic Cancer: Study startup targeted for the first half of next year (H1 2026); design includes a one-to-one randomized trial with 240 patients per arm (480 total) comparing VoPimestat + Daraxa-Rasip vs. chemotherapy.
• Dual Primary Endpoints: Response Rate (RR) and Progression-Free Survival (PFS) established for the Phase 3 design, allowing flexibility for potential early submission/accelerated approval discussions depending on data maturity.
• Second Line Strategy: FDA meeting expected before the end of 2024 to discuss accelerated approval pathways for the second-line indication; priority follows frontline initiation.

Business-Segment Outlook:

• Pancreatic Cancer: Focus shifted to "laser sharp" execution on frontline approval; data supports broad efficacy across KRAS G12D, G12V, and G12R mutations (no specific G12D monotherapy data yet, but high synergy confidence).
• Non-Small Cell Lung Cancer (NSCLC): Plan to initiate development of TNG456 (BBB-crossing PMT-5 inhibitor) in January 2027; potential strategic dichotomy where VoPimestat targets pancreas and TNG456 targets NSCLC (specifically for brain metastases).
• Glioblastoma (GBM): Current data from relapsed/refractory setting under evaluation; FDA and clinical consensus suggest adjuvant setting is the "truth," requiring attractive data to pivot to that indication; strategy update expected January 2027.
• Pipeline Expansion: Early clinical studies initiated for Eraska (0015) + VoPimestat; comprehensive development plan to be defined and announced once mutual agreement is reached with Eraska.

Market and Competitive Outlook:

• PMT-5 Landscape: Management asserts confidence in possessing the "best PMT-5 inhibitor" (VoPimestat) based on superior safety/tolerability and combinability; expects differentiation among competitors to emerge via safety and tolerability profiles rather than pure efficacy.
• Competitive Differentiation: Belief that VoPimestat's synergy with Daraxa-Rasip is unique, contrasting with lower response rates of Zoldan-Rasip combinations; no significant differentiation anticipated solely on efficacy side among existing PMT-5 inhibitors.
• Speed to Market: Company prioritizes operational speed to launch Phase 3 ahead of competitors; willing to proceed with study execution independently of supply agreements if necessary.

Macro / Industry Outlook:

• Regulatory Environment: Describes "very, very good rapport" with the FDA; agency supportive of proposed Phase 3 design and dose levels; FDA highly interested in discussing second-line accelerated approval strategy.
• Clinical Landscape: Acknowledges structural need in oncology for combinations that mitigate toxicity (e.g., skin/mucosal issues) while maintaining efficacy; views current monotherapy safety profiles as suboptimal compared to combination strategies.

Strategic Initiatives:

• Supply Chain Continuity: Actively negotiating to continue supply agreement with Revolution Medicines (RevMed) for the Phase 3 study; however, management confirms the Phase 3 start in H1 2026 will proceed without delay if an agreement is not finalized.
• Internal Capability Transformation: Completed transition from "discovery organization" (2018 baseline) to "late-stage mature development" with significant team expertise added.
• Joint Development: Advancement of Eraska collaboration (0015 + VoPimestat); initial patient dosing already underway.
• Asset Optimization: Finalizing decision on asset allocation between VoPimestat and TNG456 for NSCLC based on forthcoming data in January 2027.

Risks and Headwinds to Outlook:

• Supply Agreement Uncertainty: Risk of delay or inability to secure continued supply of Daraxa-Rasip from Revolution Medicines prior to Phase 3 startup, though deemed manageable via internal contingency.
• Regulatory Nuance: Potential unresolved questions regarding "contribution of components" for accelerated approval in the second-line setting; FDA feedback pending.
• Clinical Efficacy in Specific Mutations: Lack of specific efficacy data for G12D patients in the Daraxa-Rasip arm (currently early data), requiring continued monitoring to validate synergy assumptions.
• Indication Pivot Risk: Risk that glioblastoma data in relapsed/refractory setting may not be attractive enough to support advancement into the preferred adjuvant setting.
• Operational Complexity: High priority placed on "speed" suggests execution risks are non-trivial given the complexity of launching a 480-patient global Phase 3 trial.

Management Tone on the Future:

• High Confidence: Described current data as "reassuring," "corroborated," and "very durable"; expressed "extreme happiness" with organizational transformation.
• Aggressive Execution: Emphasis on "laser sharp" focus, "no delay" in study start, and willingness to bypass supply dependencies if needed to ensure speed.
• Strategic Certainty: Clear delineation of asset roles (VoPimestat for pancreas, TNG456 for lung/brain) pending January 2027 data confirmation; no hedging regarding the primary goal of approval.

Miscellaneous:

• Dosing Strategy: Established protocol to lower VoPimestat dose to manage toxicity, which automatically reduces Daraxa-Rasip/Raceip exposure due to drug-drug interaction dynamics.
• Safety Profile: Noted "zero" Grade 3 rash or mucositis in combination cohort; mechanism hypothesized as counterbalancing phospho-ERK upregulation (VoPimestat) with downregulation (Daraxa-Rasip).
• Timeline Milestones: Key catalysts identified as Phase 3 initiation (H1 2026), FDA discussion on 2L strategy (End of 2024), and Lung/GBM strategy updates (January 2027).